Brief: Cingulate Receives $4.3M Waiver From FDA Ahead Of Imminent Filing For Marketing Approval Of Lead Adhd Asset Ctx-1301
July 29 (Reuters) - Cingulate Inc CING.O: CINGULATE RECEIVES $4.3M WAIVER FROM FDA AHEAD OF IMMINENT FILING FOR MARKETING APPROVAL OF LEAD ADHD ASSET CTX-1301 Source text: ID:nGNX1P2kYp Further company coverage: CING.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)